Clinical Trial Update: Study of AG10 in Amyloid Cardiomyopathy [Phase 2]

View source ↗

Summary

Phase 2 trial of AG10 in amyloid cardiomyopathy (ATTR-CM) has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Attr-cm
• Wild-type Attr-cm

Drugs mentioned

• AG10

Snippet

Sponsor: Eidos Therapeutics, a BridgeBio company | Conditions: Familial ATTR-CM (ATTRm-CM, or FAC), Wild-type ATTR-CM (ATTRwt-CM) | Phase 2 | Status: COMPLETED | Results posted: 2022-11-16